IRCT20211219053450N1
Not yet recruiting
Phase 3
Effect of Empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes patients with heart failure with reduced ejection fraction
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Heart failure.
- Sponsor
- Ahvaz University of Medical Sciences
- Enrollment
- 112
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with type 2 diabetes mellitus (HbA1C\= 6\.5%) or pre\-diabetes (HbA1c between 5\.7% to 6\.4%) and ischemic heart failure with reduced fractional ejection (LVEF \= 40%)
- •over 18 years old
- •Functional NYHA Class II to IV
- •Patient consent for participation in research
Exclusion Criteria
- •Type 1 diabetes; Severe liver failure; eGFR History of diabetic ketoacidosis;
- •Existence of any malignancy and cancer;
- •Lack of adherence to the treatment regimen.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
The effect of Empagliflozin on left ventricular ejection fraction in non-diabetic patients with acute anterior ST elevation Myocardial infarction treated with primary PCIAcute anterior ST elevation Myocardial infarction treated with primary PCI.ST elevation (STEMI) myocardial infarction of anterior wallI21.0IRCT20221227056950N1Mashhad University of Medical Sciences64
Active, not recruiting
Phase 1
Impact of empagliflozin on left ventricular functionstype 2 diabetesMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2016-002225-10-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA75
Not yet recruiting
Not Applicable
The Impact of Empagliflozin on Left Ventricular Myocardial Stiffness in Heart Failure with Preserved Ejection FractioPatients with heart failure with preserved ejecion fraction (HFpEF)Drug intervention, Empagliflozin, Pressure-Volume LoopHFpEF/I509JPRN-jRCTs071230020Hieda Michinari38
Recruiting
Phase 1
The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure(ELIVE pre-HF Study)Pre-Heart Failure (Non-diabetic)Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]CTIS2024-512062-34-00niversity College Dublin100
Active, not recruiting
Phase 1
Can Empagliflozin improve the structure of the heart in those with pre-Heart Failure and is it feasible to improve physical activity by using mHealth?pre-heart failure with preserved ejection fractionMedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2022-002650-48-IEniversity College Dublin100